About this book:

"Amgen Inc.: The Story of an American Company" chronicles the remarkable journey of Amgen, tracing its evolution from a venture-backed startup founded in 1980 as Applied Molecular Genetics to one of the world's most influential biopharmaceutical giants. This comprehensive narrative delves into the scientific breakthroughs that defined its early years, notably the cloning of erythropoietin, which led to the blockbuster drug Epogen, and the development of Neupogen, revolutionizing anemia and cancer supportive care, respectively. The book highlights the visionary leadership of figures like George Rathmann and Gordon Binder, who steered the company through its critical formative phases, including its pivotal 1983 IPO and its rapid ascent to the Fortune 500, establishing its reputation for pioneering innovation and robust commercialization.

The story continues through Amgen's strategic diversification, detailing how it expanded its therapeutic reach beyond its initial successes. Key acquisitions like Immunex, which brought the autoimmune powerhouse Enbrel into its portfolio, and later, the development of next-generation medicines like Prolia and Xgeva for bone health, are explored, showcasing Amgen's relentless pursuit of new solutions for patient care. The book also covers its significant foray into direct cancer treatments through the acquisition of Onyx Pharmaceuticals and the development of its own groundbreaking BiTE therapies like Blincyto. Furthermore, it examines Amgen's strategic embrace of biosimilars, positioning the company as a key player in democratizing access to biological therapies and driving healthcare affordability.

Looking ahead, the book delves into Amgen's strategic investments in digital transformation, particularly its pioneering use of human genetics and artificial intelligence to accelerate drug discovery and development. Recent, game-changing acquisitions like Horizon Therapeutics are detailed, underscoring Amgen's commitment to expanding its footprint in rare diseases and inflammation. The narrative concludes by exploring Amgen's robust pipeline, its evolving global footprint across nearly 100 countries, its deep commitment to corporate responsibility and environmental sustainability, and the leadership of Robert A. Bradway in steering the company towards future growth in a complex and competitive industry. This book is a testament to Amgen's enduring legacy as a leader in translating scientific ingenuity into life-changing medicines, consistently addressing serious illnesses and shaping the future of global health.

What You'll Find Inside:

• **Pioneering Biotechnology:** Explore Amgen's foundational role in the biotechnology revolution, from its 1980 origins as Applied Molecular Genetics to its groundbreaking work in recombinant DNA technology.
• **Blockbuster Discoveries:** Delve into the development and transformative impact of Epogen (erythropoietin) for anemia and Neupogen (G-CSF) for cancer care, which established Amgen as a leading biopharmaceutical company.
• **Strategic Growth Through Diversification:** Understand how Amgen expanded its therapeutic reach through game-changing acquisitions like Immunex (Enbrel for inflammation) and Horizon Therapeutics (rare diseases), alongside internal innovations such as Prolia/Xgeva for bone health.
• **Commitment to Global Access and Affordability:** Discover Amgen's extensive global footprint, its push into the biosimilars market to democratize access to biological therapies, and its focus on environmental sustainability and corporate responsibility.
• **Future of Innovation with AI and Genetics:** Learn about Amgen's strategic investments in artificial intelligence, human genetics, and computational biology to accelerate drug discovery, optimize clinical trials, and develop next-generation precision medicines.

Who's It For:

This book is for anyone interested in the history of biotechnology, corporate success stories, and the development of life-changing medicines. It will particularly appeal to students and professionals in the pharmaceutical and biotech industries, investors looking for insights into leading healthcare companies, and individuals curious about the intersection of science, business, and global health impact.